SIGHT — Gensight Biologics SA Share Price
0.000.00%
Last trade - 00:00- €33.81m
- €50.46m
- €1.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 22.54 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1054.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 4.39 | 5.28 | 2.58 | 1.27 | 1.5 | 4.83 | 4.47 | 16.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Directors
- Michael Wyzga NEC (66)
- Bernard Gilly CEO
- Marie-claude Holtz DCE
- Thomas Gidoin CFO
- Marion Ghibaudo CTO
- Magali Taiel OTH
- Cedric Moreau DRC
- Elsy Boglioli IND
- Francoise De Craecker IND
- Peter Goodfellow IND (70)
- Maritza McIntyre IND
- Simone Seiter IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 17th, 2012
- Public Since
- July 13th, 2016
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 124,316,651
- Address
- 74 Rue du Faubourg Saint-Antoine, PARIS, 75012
- Web
- https://www.gensight-biologics.com/
- Phone
- +33 176217220
- Auditors
- Deloitte & Associes
Upcoming Events for SIGHT
Gensight Biologics SA Annual Shareholders Meeting
Q2 2025 Gensight Biologics SA Corporate Sales Release
Half Year 2025 Gensight Biologics SA Earnings Release
Q3 2025 Gensight Biologics SA Corporate Sales Release
Similar to SIGHT
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the Gensight Biologics SA share price?
As of Today at 02:47 UTC, shares in Gensight Biologics SA are trading at €0.27. This share price information is delayed by 15 minutes.
How has the Gensight Biologics SA share price performed this year?
Shares in Gensight Biologics SA last closed at €0.27 and the price had moved by -34.93% over the past 365 days. In terms of relative price strength the Gensight Biologics SA share price has underperformed the FTSE Global All Cap Index by -36.56% over the past year.
What are the analyst and broker recommendations for Gensight Biologics SA?
The overall consensus recommendation for Gensight Biologics SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gensight Biologics SA dividend yield?
Gensight Biologics SA does not currently pay a dividend.
Does Gensight Biologics SA pay a dividend?
Gensight Biologics SA does not currently pay a dividend.
When does Gensight Biologics SA next pay dividends?
Gensight Biologics SA does not currently pay a dividend.
How do I buy Gensight Biologics SA shares?
To buy shares in Gensight Biologics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gensight Biologics SA?
As of the previous close price of €0.27, shares in Gensight Biologics SA had a market capitalisation of €33.81m.
Where are Gensight Biologics SA shares listed?
Here are the trading details for Gensight Biologics SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: SIGHT
What kind of share is Gensight Biologics SA?
Based on an overall assessment of its quality, value and momentum Gensight Biologics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gensight Biologics SA share price forecast for 2025?
The analyst consensus target price for shares in Gensight Biologics SA is €0.40. That is 47.06% above the last closing price of €0.27.
Analysts covering Gensight Biologics SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.43 for the next financial year.
Find out moreWhat is the trend in the Gensight Biologics SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gensight Biologics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -10.35%.
As of the last closing price of €0.27, shares in Gensight Biologics SA were trading -11.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gensight Biologics SA PE Ratio?
The Gensight Biologics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gensight Biologics SA?
Gensight Biologics SA's management team is headed by:
- Michael Wyzga - NEC
- Bernard Gilly - CEO
- Marie-claude Holtz - DCE
- Thomas Gidoin - CFO
- Marion Ghibaudo - CTO
- Magali Taiel - OTH
- Cedric Moreau - DRC
- Elsy Boglioli - IND
- Francoise De Craecker - IND
- Peter Goodfellow - IND
- Maritza McIntyre - IND
- Simone Seiter - IND